About KOMZIFTI™ KOMZIFTI (ziftomenib) is an oral menin inhibitor approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation ...

The U.S. Food and Drug Administration has approved Novartis' gene therapy for patients with a rare muscle disorder, the drugmaker said on Monday.

The American Gastroenterological Association (AGA) has released a comprehensively updated clinical guideline on the ...

Medical research is ultimately not just about curing disease — it’s about creating a healthier, longer and higher-quality life for everyone.

Early intervention and effective therapies are transforming multiple sclerosis management, enhancing patient outcomes, and delaying disability progression.

Pneumonia, a largely preventable disease, caused more than two million deaths in 2021, according to the Global Burden of ...

MONDAY, Nov. 10, 2025 (HealthDay News) — Multiple sclerosis (MS) is one of the most common autoimmune diseases affecting the brain and spinal cord, with 2.9 million people estimated to be living with ...

For the first time, sexual medicine experts have created treatment guidelines and recommendations for women who experience low sexual desire or Hypoactive Sexual Desire Disorder (HSDD), a common yet ...

When Jean Kay started a brand-new multiple sclerosis treatment called Rebif in 2003, it cost $17,500 a year. That was pricey, but her insurance covered most of it, and the drug slowed the disease’s ...

Doctors now have new tools to diagnose multiple sclerosis, or MS, earlier, sometimes even before a person experiences the symptoms of the autoimmune disease. MS is a disease where the immune system ...